Abstract
For many autoimmune diseases, definitions of disease and patient heterogeneity are major concerns. Response to treatment varies greatly between patients, and this variability might obstruct clinical trials. Many drug candidates have not shown efficacy in patients with systemic autoimmune diseases and thus will not reach the market, despite excellent responses in individual patients or subgroups of patients. Stratification of patients is therefore of high priority, but no validated biomarkers to define relevant subgroups of patients with primary Sjögren's syndrome exist.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
